Experiment Overview
| Repository ID: | FR-FCM-Z3KD | Experiment name: | Flow Cytometry profiles of TIL co-expressing CD39, CD103, and PD-1 in ovarian cancer | MIFlowCyt score: | 64.25% |
| Primary researcher: | Julian Smazynski | PI/manager: | Brad Nelson | Uploaded by: | Julian Smazynski |
| Experiment dates: | 2020-02-01 - | Dataset uploaded: | Mar 2021 | Last updated: | Mar 2021 |
| Keywords: | [PD-1] [immunotherapy] [TIL] [TIGIT] [CD39] [CD103] [Ovarian cancer] | Manuscripts: | |||
| Organizations: |
BC Cancer, Deeley Research Centre, Victoria, British Columbia (Canada)
|
||||
| Purpose: | Defining TIL subsets in ovarian cancer which drive prognostic significance. Expression of CD39, CD103, PD-1, and other immune markers was assessed by high-dimensional flow cytometry in matched primary ovarian/ascites patient samples. Healthy donor PBMC were also profiled as a reference control. | ||||
| Conclusion: | CD39, CD103, and PD-1 are highly co-expressed on ovarian TIL | ||||
| Comments: | A 20-parameter panel was used to profile cell surface immune checkpoint molecules by spectral flow cytometry on a Cytek Aurora 3 laser (Red/Blue/Violet) instrument(Cytek, Fremont CA). Representative gating strategies and full panel design can be found in the associated manuscript (Title and author list below). Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer Céline M. Laumont, Maartje C.A. Wouters, Julian Smazynski, Nicole S. Gierc, Elizabeth A. Chavez, Lauren C. Chong, Shelby Thornton, Katy Milne, John R. Webb, Christian Steidl, Brad H. Nelson | ||||
| Funding: | Not disclosed | ||||
| Quality control: | Flow Cytometry Data | Ovarian and Ascites samples are from matched primary specimens. 5 healthy donor PBMC samples were also stained with the full panel. FMO controls were performed on each specimen type for the specified target antigens. All samples were spectrally unmixed and corrected using single stain reference controls in Spectroflo software. Data includes both Raw and Unmixed files. | |||
Experiment variables
| Conditions | |
|---|---|
| · FMO | CCR7 ASCITES FMO.fcs · CCR7 PBMC FMO.fcs · CCR7 TUMOR FMO.fcs · CD103 ASCITES FMO.fcs · CD103 PBMC FMO.fcs · CD103 TUMOR FMO.fcs · CD127 ASCITES FMO.fcs · CD127 PBMC FMO.fcs · CD127 TUMOR FMO.fcs · CD138 ASCITES FMO.fcs · CD138 PBMC FMO.fcs · CD138 TUMOR FMO.fcs · CD14 ASCITES FMO.fcs · CD14 PBMC FMO.fcs · CD14 TUMOR FMO.fcs · CD25 ASCITES FMO.fcs · CD25 PBMC FMO.fcs · CD25 TUMOR FMO.fcs · CD39 ASCITES FMO.fcs · CD39 PBMC FMO.fcs · CD39 TUMOR FMO.fcs · CD45 ASCITES FMO.fcs · CD45 PBMC FMO.fcs · CD45 TUMOR FMO.fcs · CD45RA ASCITES FMO.fcs · CD45RA PBMC FMO.fcs · CD45RA TUMOR FMO.fcs · CD56 ASCITES FMO.fcs · CD56 PBMC FMO.fcs · CD56 TUMOR FMO.fcs · CD69 ASCITES FMO.fcs · CD69 PBMC FMO.fcs · CD69 TUMOR FMO.fcs · CD95 ASCITES FMO.fcs · CD95 PBMC FMO.fcs · CD95 TUMOR FMO.fcs · CTLA4 ASCITES FMO.fcs · CTLA4 PBMC FMO.fcs · CTLA4 TUMOR FMO.fcs · HLADR ASCITES FMO.fcs · HLADR PBMC FMO.fcs · HLADR TUMOR FMO.fcs · PD1 ASCITES FMO.fcs · PD1 PBMC FMO.fcs · PD1 TUMOR FMO.fcs · TIGIT ASCITES FMO.fcs · TIGIT PBMC FMO.fcs · TIGIT TUMOR FMO.fcs · TIM3 ASCITES FMO.fcs · TIM3 PBMC FMO.fcs · TIM3 TUMOR FMO.fcs |
| · TUMOR | cd39-01-s10 TUMOR.fcs · cd39-01-s11 TUMOR.fcs · cd39-01-s12 TUMOR.fcs · cd39-01-s2 TUMOR.fcs · cd39-01-s3 TUMOR.fcs · cd39-01-s4 TUMOR.fcs · cd39-01-s5 TUMOR.fcs · cd39-01-s6 TUMOR.fcs · cd39-01-s7 TUMOR.fcs · cd39-01-s8 TUMOR.fcs · cd39-01-s9 TUMOR.fcs · cd39_01_s1 TUMOR.fcs |
| · ASCITES | cd39-01-s1 ASCITES.fcs · cd39-01-s10 ASCITES.fcs · cd39-01-s11 ASCITES.fcs · cd39-01-s12 ASCITES.fcs · cd39-01-s2 ASCITES.fcs · cd39-01-s3 ASCITES.fcs · cd39-01-s5 ASCITES.fcs · cd39-01-s6 ASCITES.fcs · cd39-01-s7 ASCITES.fcs · cd39-01-s8 ASCITES.fcs · cd39-01-s9 ASCITES.fcs |
| · PBMC | LP1 CD39 PBMC.fcs · LP2 CD39 PBMC.fcs · LP3 CD39 PBMC.fcs · LP4 CD39 PBMC.fcs · LP5 CD39 PBMC.fcs |
